Literature DB >> 19526991

A [3]ferrocenophane polyphenol showing a remarkable antiproliferative activity on breast and prostate cancer cell lines.

Damian Plazuk1, Anne Vessières, Elizabeth A Hillard, Olivier Buriez, Eric Labbé, Pascal Pigeon, Marie-Aude Plamont, Christian Amatore, Janusz Zakrzewski, Gérard Jaouen.   

Abstract

We have previously shown that modification of polyphenols with a ferrocenyl group can dramatically enhance their cytotoxicity. We now present two new [3]ferrocenophane compounds, one of which has an antiproliferative effect seven times stronger than the corresponding noncyclic species, with IC50 values of 90 and 94 nM on hormone-independent MDA-MB-231 breast and PC-3 prostate cancer cell lines, respectively. Solubility studies in water using methylated beta-cyclodextrin and electron transfer studies are also presented.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19526991     DOI： 10.1021/jm900297x

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


  8 in total

1.  Ferrocenyl 2,5-Piperazinediones as Tubulin-Binding Organometallic ABCB1 and ABCG2 Inhibitors Active against MDR Cells.

Authors:  Anna Wieczorek; Andrzej Błauż; Janusz Zakrzewski; Błażej Rychlik; Damian Plażuk
Journal:  ACS Med Chem Lett       Date:  2016-02-22       Impact factor: 4.345

2.  Development of selective estrogen receptor modulator (SERM)-like activity through an indirect mechanism of estrogen receptor antagonism: defining the binding mode of 7-oxabicyclo[2.2.1]hept-5-ene scaffold core ligands.

Authors:  Yangfan Zheng; Manghong Zhu; Sathish Srinivasan; Jerome C Nwachukwu; Valerie Cavett; Jian Min; Kathryn E Carlson; Pengcheng Wang; Chune Dong; John A Katzenellenbogen; Kendall W Nettles; Hai-Bing Zhou
Journal:  ChemMedChem       Date:  2012-04-19       Impact factor: 3.466

3.  Chemical alternative for cell identification and cross-contamination detection.

Authors:  Dhouha Msalbi; Jihene Elloumi-Mseddi; Bochra Hakim; Emna Sahli; Sami Aifa
Journal:  3 Biotech       Date:  2022-02-25       Impact factor: 2.406

4.  Metallocenes as Target Specific Drugs for Cancer Treatment.

Authors:  Enrique Meléndez
Journal:  Inorganica Chim Acta       Date:  2012-06-21       Impact factor: 2.545

Review 5.  Organometallic anticancer compounds.

Authors:  Gilles Gasser; Ingo Ott; Nils Metzler-Nolte
Journal:  J Med Chem       Date:  2010-11-15       Impact factor: 7.446

6.  Targeting Antioxidant Pathways with Ferrocenylated N-Heterocyclic Carbene Supported Gold(I) Complexes in A549 Lung Cancer Cells.

Authors:  J F Arambula; R McCall; K J Sidoran; D Magda; N A Mitchell; C W Bielawski; V M Lynch; J L Sessler; K Arumugam
Journal:  Chem Sci       Date:  2015-10-29       Impact factor: 9.825

7.  Synthesis, Electrochemical and Fluorescence Properties of the First Fluorescent Member of the Ferrocifen Family and of Its Oxidized Derivatives.

Authors:  Charles Fayolle; Pascal Pigeon; Nathalie Fischer-Durand; Michèle Salmain; Olivier Buriez; Anne Vessières; Eric Labbé
Journal:  Molecules       Date:  2022-10-08       Impact factor: 4.927

8.  On the discovery, biological effects, and use of Cisplatin and metallocenes in anticancer chemotherapy.

Authors:  Santiago Gómez-Ruiz; Danijela Maksimović-Ivanić; Sanja Mijatović; Goran N Kaluđerović
Journal:  Bioinorg Chem Appl       Date:  2012-07-12       Impact factor: 7.778
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.